A new Phase III clinical trial presented at the American Stroke Association’s International Stroke Conference 2026 found that stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, within 48 hours of symptom onset had a higher rate of excellent functional recovery at 90 days compared to those who received a placebo. The study, conducted at 32 centers in China, enrolled 998 adults aged 18 to 80 with moderate to severe ischemic stroke.
Participants received daily infusions of 40 mg loberamisal or a matched placebo for 10 days, starting within 48 hours of stroke onset. At 90 days, 69% of those in the loberamisal group achieved a score of 0-1 on the modified Rankin Scale, indicating little to no disability, compared to 56% in the placebo group. The treatment was deemed safe, with no increased risk of serious side effects or death.
Loberamisal is a dual-target neuroprotective agent designed to preserve the function of neurovascular units, a strategy that has faced challenges in previous trials. The American Stroke Association’s 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke notes renewed interest in neuroprotection, highlighting the need for further research. Study author Shuya Li, M.D., director of the Clinical Trial Center at Beijing Tiantan Hospital, emphasized that multi-target agents like loberamisal could lead to important advancements in reducing post-stroke disability.
Limitations of the study include its conduct solely in China, which may limit generalizability to other populations. Only about 17% of participants received standard IV clot-busting medication, and patients who underwent mechanical thrombectomy were excluded. No blood or imaging biomarkers were assessed, limiting understanding of the drug’s mechanism. The researchers plan to confirm findings in larger, more diverse groups and explore biomarkers.
Despite these limitations, the results offer hope for a new treatment option in acute ischemic stroke. The American Heart Association’s 2026 Heart Disease and Stroke Statistics indicate stroke is now the fourth leading cause of death in the U.S. For more information on stroke types and treatment, visit the American Heart Association’s resources at stroke.org and the American Stroke Association’s acute ischemic stroke resources at heart.org.
The full study abstract is available in the American Stroke Association International Stroke Conference 2026 Online Program Planner. The findings are considered preliminary until published in a peer-reviewed journal.
